Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KLH + melanoma peptides + dendritic cells
- Development stage
- Unknown
- Lead developer
- Dr. Nina Bhardwaj
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This experimental autologous dendritic cell vaccine was developed by Dr. Nina Bhardwaj for the treatment of high-risk resected melanoma. The therapeutic approach involves isolating a patient's own dendritic cells (DCs) and maturing them ex vivo while pulsing them with five specific melanoma-associated peptides and Keyhole Limpet Hemocyanin (KLH). KLH serves as a potent immunogenic carrier and adjuvant to enhance the overall immune response and acts as a tracer to monitor immune competence. The matured, antigen-loaded dendritic cells are administered intradermally to the patient, where they migrate to the lymph nodes to prime and activate cytotoxic T lymphocytes (CTLs) against melanoma cells expressing the targeted antigens. This vaccine was evaluated in Phase 1 clinical trials to compare the efficacy of dendritic cells versus standard adjuvants like Montanide in inducing anti-tumor immunity.
- Other names
- KLH + peptides + dendritic cells-Dr. Nina Bhardwaj-melanomaMelanoma peptide-pulsed dendritic cell vaccineDC-peptide vaccine with KLH
Beyond the preview
Go deeper on KLH + melanoma peptides + dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KLH + melanoma peptides + dendritic cells.